Core Insights - The Tianjin government has approved the inclusion of a section of the Baodi District Zhongguancun Science and Technology City into the Tianjin Kaiyuan High Education and Innovation Park's "one core, two wings, multiple points" spatial development layout, expanding the "multiple points" to six [1][2] Group 1 - The newly included area covers 3.22 square kilometers, bordered by Zong San Road and Kaiyuan Road to the east, Chaoxia Road to the west, Heng San Road to the south, and the southern boundary of the Beijing-Harbin Expressway green belt to the north [1] - The Baodi District Zhongguancun Science and Technology City is the only major asset held by Zhongguancun Development Group outside of Beijing, serving as an important platform for implementing the Beijing-Tianjin-Hebei coordinated development strategy [1][2] Group 2 - The area has favorable conditions for spatial capacity, initial industrial development, accelerated gathering of innovation resources, and smooth channels for achievement transformation [2] - The Tianjin Kaiyuan Park Management Committee will guide local governments to leverage the close connection with Zhongguancun, enhance the brand strength of Tianjin Kaiyuan Park, and actively introduce Zhongguancun's innovation resources [2] - Key industries to be developed include biomedicine and medical devices, new materials, and the integration of industrial chains, innovation chains, supply chains, capital chains, and talent chains [2]

【 机构观点综评 】招商证券称，政策平稳发力，债市环境友好。摩根基金认为，A股市场中有许 多具有全球竞争力的企业仍被严重低估，从长期来看，它们具有非常大的投资机会。 一、焦点锐评 1.政治局：要加紧实施更加积极有为的宏观政策 4月25日，中共中央政治局召开会议，分析研究当前经济形势和经济工作。会议指出，以高质量 发展的确定性应对外部环境急剧变化的不确定性。会议强调，要加紧实施更加积极有为的宏观政 策，用好用足更加积极的财政政策和适度宽松的货币政策。加快地方政府专项债券、超长期特别 国债等发行使用。适时降准降息，保持流动性充裕。要不断完善稳就业稳经济的政策工具箱，既 定政策早出台早见效，根据形势变化及时推出增量储备政策，加强超常规逆周期调节，全力巩固 经济发展和社会稳定的基本面。 【点评】广发证券表述，本次政治局会议有三大特点，一是主线明确，"以高质量发展的确定性 应对外部环境急剧变化的不确定性"，做好"底线"和"预案"。二是政策具备广谱性，有带动固定资 产投资的政策，也有带动消费的政策；有带动传统部门的政策，也有带动新兴部门的政策。三是 政策整体集中于见效较快的领域。国泰基金认为，从会议来看，未来政策有望继续 ...

Core Viewpoint - The report from China Europe Fund highlights the performance and strategic outlook of three funds managed by renowned fund manager Ge Lan, focusing on the healthcare and innovation sectors, indicating a positive trend in the Chinese pharmaceutical and medical device markets [1][3]. Fund Performance - The largest fund, China Europe Healthcare Mixed Fund, reported a net value growth rate of 2.37% for Class A shares and 2.17% for Class C shares, outperforming the benchmark return of 0.46% during the same period [3]. - The top ten holdings of the fund include major companies such as Heng Rui Medicine, WuXi AppTec, and Mindray Medical, with notable changes in the portfolio compared to the end of 2024 [3]. Market Environment - The overall policy environment continues to support innovation while reinforcing compliance, with the National Medical Insurance Administration exploring a new category for Class B drugs, which expands payment options for innovative drugs [3]. - The normalization of anti-corruption and price governance in the pharmaceutical sector is leading companies to enhance their academic promotion systems, fostering a healthier and more sustainable domestic medical market [3]. Innovation and Collaboration - The report emphasizes the acceleration of research and development in innovative drugs, particularly in areas like multi-antibody and ADC technologies, with increasing collaboration between domestic companies and international firms [4]. - Key clinical data disclosures and ongoing global partnerships are expected to enhance the competitiveness of Chinese companies in the ADC, multi-antibody, and peptide sectors [4]. Consumer Healthcare and Medical Devices - The consumer healthcare sector is anticipated to see structural opportunities, particularly in aesthetic medicine and ophthalmology, driven by rising health management awareness among residents [4]. - The demand for home medical devices is projected to grow steadily due to the aging population, while the medical device sector is recovering, with significant growth in domestic bidding data observed in the first quarter [4].